Felice Verduyn-van Weegen joined LSP in 2015 as an associate and became an Investment Manager in 2019. Felice is part of the LSP investment team focused on unlisted equities, and is involved in all stages of the investment process. She has been involved in a large number of LSP’s investments and is a Board Director of AM-pharma and Alizé Pharma 3 and Board Observer of Pharvaris and OxThera.
Prior to joining LSP, Felice was a consultant at McKinsey & Company where she worked on projects in the Netherlands and internationally with a prime focus on healthcare and technology. Before McKinsey, she was a neuroscientist and statistical geneticist, working with the prestigious complex traits genetics group at the Broad Institute and Harvard Medical School in Cambridge, USA. Her focus of research was on modelling complex disease genetics using large sequencing datasets. Prior to that, she worked with the department of Biological Psychology at the VU University in Amsterdam, The Netherlands. Her research there focused on predicting heritability of complex disorders using twin datasets. Felice authored a number of scientific articles in prestigious journals. At the VU University in Amsterdam, Felice was awarded a Bachelor’s degree in Biological Psychology and a Master’s degree in Neuroscience. In addition, she completed business studies by graduating with an MBA degree from Columbia Business School, New York USA. Felice lives in Amsterdam with her husband and daughter.
To contact Felice directly, email email@example.com or call +31 (0) 20 664 55 00.